FLUOXETINE HYDROCHLORIDE; OLANZAPINE | N021520 | ELI LILLY AND CO
5 strengths0 unique patents0 unique exclusivities
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
Para IV certification filed but no ANDA patent litigation cases (NOS 835) matched from PACER. Litigation may be pending or filed under a different caption.
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (5)
Sort:
#001 — EQ 25MG BASE;EQ 3MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
RLD
0 patents0 exclusivities▴
CAPSULE;ORAL | Approved: Apr 9, 2007
No patent or exclusivity listings for this strength.
#002 — EQ 25MG BASE;EQ 6MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
RLD
0 patents0 exclusivities▾
CAPSULE;ORAL | Approved: Dec 24, 2003
#003 — EQ 50MG BASE;EQ 6MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
RLD
0 patents0 exclusivities▾
CAPSULE;ORAL | Approved: Dec 24, 2003
#004 — EQ 25MG BASE;EQ 12MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
RLD
0 patents0 exclusivities▾
CAPSULE;ORAL | Approved: Dec 24, 2003
#005 — EQ 50MG BASE;EQ 12MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**